Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Introduction Since the soluble receptor activator of the NF-kappaB ligand (sRANKL) as well as the endogenous anti-resorptive cytokine osteoprotegerin (OPG) are produced by osteoblasts and given that these cells undergo significant changes during antiresorptive treatment, we hypothesized that treatment with bisphosphonates (BP) would be accompanied by changes in serum OPG and sRANKL levels.Methods In a prospective, randomized controlled trial of previously untreated postmenopausal women with osteoporosis, oral BP therapy (daily doses of either 10 mg alendronate or 5 mg risedronate) in combination with calcium/vitamin D was compared to calcium/vitamin D treatment alone (control group). Follow-up at 2, 6 and 12 months was completed for 56 patients. Standardized spinal X-rays were performed at baseline, and DEXA measurements at the femoral neck and trochanter were made at baseline and after 1 year. Serum OPG and sRANKL levels were measured with a polyclonal antibody-based ELISA system.Results After 1 year, there was a non-significant loss in neck and trochanteric bone mineral density (BMD) in the CTR group and a mean increase of 3.3% and 4.6% in the combined BP group (both p<0.0001), respectively. Serum levels of C-terminal telopeptides of type I collagen (sCTX) and osteocalcin decreased by 12% and 10% at 12 months in the CTR group and by 43% and 23% in the combined BP group, respectively (all significant). OPG serum levels in the CTR group decreased significantly by 9% at 2 months (p<0.005) and remained below pre-treatment levels at later time points. Both the alendronate- and risedronate-treated patient groups showed unaltered OPG levels after 2 months, but they had significantly increased serum levels at 6 and 12 months. Levels of sRANKL were unchanged throughout the treatment period. Univariate regression analysis demonstrated that changes in serum OPG levels after 12 months of BP treatment were positively and better correlated to BMD changes (trochanter: r=0.59, p<0.0001; neck: r=0.50, p<0.001) than those of sCTX, which showed the expected negative correlation to BMD change (trochanter: r=-0.35, p=0.03; neck: r=-0.23, p=0.16). With multiple regression analyses at 12 months, R2 values for 1-year changes in trochanteric BMD of 0.33 (OPG alone) and 0.23 (sCTX alone) were significantly improved to the 0.57 when OPG and sCTX changes were combined (p<0.001). Results for the femoral neck were also statistically significant R2=0.35, p<0.001). BMD and OPG changes in the CTR group were not correlated with each other.Conclusions We conclude that with BP treatment, changes in serum OPG levels, unlike changes in sCTX levels, are positively correlated to changes in BMD response. The BP-related changes in serum OPG levels during treatment could result from effects on osteoclastogenesis and osteoclast apoptosis as well as from a direct stimulatory effect on osteoblastic OPG production. These changes in OPG levels may be used to predict the individual response of patients to BP treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, a study of oral bisphosphonates in postmenopausal women found a positive correlation between changes in serum OPG levels and BMD response (390).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [390]
Citations
Cites
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691 · cited 1×
“[31], a prevalent vertebral fracture was diagnosed when there was a ≥20% reduction in any of the anterior, middle or posterior height ratios of the vertebral body compared to undeformed adjacent vertebrae.”
BackgroundLips, P. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.4.0437 · Cited by 2,118 · cited 1×
“The decrease in PTH, whichwas on the order of 10%with calcium/ vitamin D supplementation, suggests the presence of a mild deficiency of vitamin D in our patients at baseline [41].”
BackgroundLuckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176 · cited 1×
“pathway [1] and increase the production of Apppi, an ATP”
BackgroundBisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040 · cited 1×
“BP have a direct antiresorptive effect on osteoclasts [37] that feeds back on osteoblast activity by decreasing the proliferation and differentiation of osteoblasts via a coupling mechanism that is still poorly defined.”
BackgroundRole of osteoblasts in hormonal control of bone resorption—A hypothesis
Rodan, G. A., & Martin, T. J. (1981) · Calcified Tissue International · doi:10.1007/bf02409454 · Cited by 982
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890 · cited 1×
“Recent reports propose that BP are capable of stimulating differentiation and inhibiting proliferation of the human fetal osteoblastic lineage cell line hFOB [10] and of decreasing osteoblastic apoptosis in murine vertebral cancellous bone cells [11].”
BackgroundBoivin, G. Y., Chavassieux, P. M., Santora, A. C., Yates, J., & Meunier, P. J. (2000) · Bone · doi:10.1016/s8756-3282(00)00376-8 · Cited by 574
Chavassieux, P. M., Arlot, M. E., Reda, C., Wei, L., Yates, A. J., & Meunier, P. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119668 · Cited by 523 · cited 1×
“This phenomenon is also reflected by the finding of an 80–90% decrease in the mineralizing surface of transiliac bone specimens 6 and 12 months after the initiation of BP treatment [38, 39].”
Result
Research works printed but not linked: 2
- Mönkkönen H, Lehenkari PP, Kellinsalmi M (2004) A new mechanism of action for bisphosphonates: apppi dedicated cytotoxicity of N-BPs. Bone 34:S66–S67
- Sankaralingam S, Frost M, Fogelman I, Hampson G (2003) Early changes in serum osteoprotegerin (OPG) correlates with changes in bone mineral density following treatment with risedronate in post-menopausal women with osteoporosis (Abstract). J Bone Miner Res 18:S158
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003376.pub3 · Cited by 499
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001155.pub2 · Cited by 401
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004523.pub3 · Cited by 211
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
Baud’huin, M., Lamoureux, F., Duplomb, L., Rédini, F., & Heymann, D. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7104-0 · Cited by 170
Metadata
- Authors
- Dobnig, H., Hofbauer, L. C., Viereck, V., Obermayer-Pietsch, B., & Fahrleitner-Pammer, A.
- Affiliations
- University of Graz (AT)
- Philipps University of Marburg (DE)
- University of Göttingen (DE)
- Corresponding author
- Dobnig, H.
- Venue
- Osteoporosis International
- Published
- 2006-01-25
- Volume
- 17
- Issue
- 5
- Pages
- 693-703
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2075929809
- Cited by
- 76
- References
- 42
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2022: 2 · 2021: 2 · 2020: 2 · 2017: 2 · 2016: 4 · 2015: 1 · 2014: 2 · 2013: 4 · 2012: 4
- FWCI
- 11.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- RANK ligand, osteoprotegerin, bisphosphonates, alendronate, risedronate, osteoporosis, bone mineral density, postmenopausal women, bone resorption, osteocalcin, C-terminal telopeptide of type I collagen, calcium and vitamin D supplementation, antiresorptive therapy, serum biomarkers, femoral neck
- MeSH terms
- Risedronic Acid, Aged, Female, Hip, Humans, Osteoporosis, Prospective Studies, Etidronic Acid, Absorptiometry, Photon, Bone Density, Osteocalcin, Bone Remodeling, Postmenopause, Alendronate, Collagen Type I, Bone Density Conservation Agents, Osteoprotegerin, RANK Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. https://app.cochat.ai/papers/10.1007/s00198-005-0035-4
- The paper
- Dobnig, H., Hofbauer, L. C., Viereck, V., Obermayer-Pietsch, B., & Fahrleitner-Pammer, A. (2006). Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporosis International. https://doi.org/10.1007/s00198-005-0035-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.